Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson
CEO, Wayne Paterson
Source: Anteris Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Structural heart company Anteris Technologies (AVR) has received a United States patent for its sterilisation method
  • The sterilisation method can be used with a collagen-based biomaterial and was invented by Professor Leon Neething
  • Sterilisation is an important step in the company’s ADAPT tissue technology process and is a key in its manufacturing of ADAPT
  • On the market this afternoon, Anteris is down 0.25 per cent and is trading for $3.99 per share

Structural heart company Anteris Technologies (AVR) has received a United States patent for its sterilisation method.

The patent was granted by the United States Patent Office. The sterilisation method can be used with a collagen-based biomaterial and was invented by Professor Leon Neething. Leon is currently the Vice President of Cardiovascular Technologies at Anteris and is also a professor ar School of Surgery in the University of Western Australia.

Sterilisation is an important step in the company’s ADAPT tissue technology process and is a key in its manufacturing of ADAPT.

ADAPT tissue platform is a next-generation technology with zero DNA and zero glutaraldehyde (Cidex). It is the only bio-scaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery.

“Expanding our intellectual property portfolio is an area of continual focus,” Chief Executive Officer Wayne Paterson said.

“The ADAPT tissue is a vital component of our DuraAVR single-piece 3D aortic valve, and therefore extending the IP portfolio is essential to our value creation strategy,” he added.

On the market this afternoon, Anteris is down 0.25 per cent and is trading for $3.99 per share at 2:43 pm AEST.

AVR by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…